Companies › Biocomposites
1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STIMULAN VG Bioabsorbable composite of gentamicin and calcium sulfate | – | Phase 2 | Diabetic Foot Osteomyelitis; Pressure Ulcer, Stage IV | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05539963 | STIMULAN VG | Phase 2 | Diabetic Foot Osteomyelitis | Metabolic and endocrine | Jun 2026 |
| NCT06283979 | STIMULAN VG | Phase 2 | Pressure Ulcer, Stage IV | Immunology | Dec 2026 |
No annotated target.
–
Red de Terapia Celular Tiger Biosciences Immunis Nature Cell Throne Biotechnologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.